Media Center

IAVI in the News - 2017

November

Four big insights into HIV/AIDS that provide hope of finding a vaccine: Thumbi Ndung'u describes the cutting-edge research African scientists are engaged in toward an HIV vaccine. The Citizen

Working alongside a number of partner organizations, including IAVI, Janssen continues to make dramatic improvements for patients with HIV. Pharmafile 

To address the challenges of providing more people with access to antiretroviral therapy in India, IAVI along with the Centers for Disease Control and Prevention came together in the national capital on Friday to discuss ways to accelerate HIV treatment prevention. “Globally, innovative programmes have been launched to tackle infectious diseases. These programmes must be integrated to address the problem, and countries across the world must develop end-to-end research capability which will, in turn, accelerate outcomes,” said Rajat Goyal, India Country Director of IAVI, in eHealth.

Thumbi Ndung'u, Scientific Director of the HIV Pathogenesis Programme (HPP) at the Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, which is one of IAVI's partners in South Africa, has been awarded a gold medal for his contributions to HIV and TB research by the 2017 South African Medical Research Council. The awards are among South Africa's most prestigious. Gold medals are awarded annually to established senior scientists who have made key contributions that have had an impact on the health of people. Africa Health Research Institute


October

Former IAVI CEO Margie McGlynn has been honored with a Lifetime Achievement Award as part of the PM360 Trailblazer Awards. “From her first day, Margie coordinated the workload in a strategic and effective way, so that each candidate vaccine was given the best chance to be successful. That is complicated enough when it comes to success in the U.S., but Margie was thinking globally,” says Mark Feinberg. PM360

“We’re closer than we’ve ever been. I think that there will be meaningful biological intervention that will have a significant impact on preventing HIV infection in the coming 5 years that will help bend the curve of HIV infection rates downward in a significant way,” says Mark Feinberg in MD Magazine.

“There is a great deal of energy at every stage of the development pipeline – from promising antibody discoveries to novel vaccine platforms, from early-phase clinical trials to one very large efficacy trial now being conducted in South Africa,” says Mark Feinberg in MD Magazine.

 

September

Progress in fighting HIV 'could save lung cancer victims too': Recently awarded a Pioneer grant from Cancer Research UK, IAVI's Jonathan Hare joins forces with cancer researchers to explore immunological similarities between HIV and lung cancer. Evening Standard.

“We learned in this study that grabbing hold of these glycans can be a very important early step in an effective immune response to HIV, and with this knowledge, we believe we can design better candidate vaccines,” says Dennis Burton in this TSRI news release.

 

August

Janssen Vaccines and Prevention B.V. is now rapidly advancing an experimental prime-boost HIV vaccine regimen, with plans announced at the IAS 2017 conference to launch a large-scale "proof of concept" efficacy trial in women in late 2017/early 2018, in collaboration with IAVI and several other organizations: The Body Pro

 

July

"We have been doing immunization experiments in different animal models for years. For this to work so well, quickly and reliably was above and beyond what we expected," says Devin Sok in The Body Pro.

Dennis Burton reacts to another milestone step toward the long-elusive aim of creating a vaccine against HIV; and Mark Feinberg comments on news coming out of the 9th IAS Conference on HIV Science in Paris: The San Diego Union-Tribune

Devin Sok: "The response blew our minds. It was just insane how good it looked, in humans it takes three-to-five years to develop the antibodies we're talking about. Who would have thought cow biology was making a significant contribution to HIV." BBC

Devin Sok reacts to his study showing that with a little cellular engineering, cow-made antibodies could one day be used for short-term protection or to treat HIV-infected individuals: The Scientist

IAVI's Devin Sok, director of antibody discovery and development, speaks about how cows are helping scientists better understand how to prevent HIV infections in humans: Time

IAVI's Javier Guenaga comments on the promising HIV research developments happening at The Scripps Research Institute: DDNews

 

June

Dennis Burton comments on the promise of optimized immunizations that reliably elicit protective antibodies in preclinical study: Science Daily

Leslie Nielsen, Director, Africa Parnerships at IAVI, comments on local scientists setting the agenda so that research responds to solving local problems: New Vision

 

May

"This is an important opportunity to test how prepared countries are to decide whether or not they want to deploy new vaccines, and how, before they are licensed,” says Mark Feinberg in Nature

 

January

Anant Bhan, senior manager of IAVI's India program, offers advice to India's rural health journalists: International Journalists' Network

Mark Feinberg and fellow global health experts from the newly formed Coalition for Epidemic Preparedness Innovations on why we need new vaccines against epidemic infectious diseases: New England Journal of Medicine

"We're not prepared for future Ebola outbreaks," warn Mark Feinberg and other leading infectious disease experts in STAT

Mark Feinberg, Financial Times: “The development of an HIV vaccine is probably the greatest challenge that biomedical science has taken on in the public health arena.”